Last updated on April 19, 2014 at 21:20 EDT

Transition Therapeutics Announces ELND005 Presentations at the Clinical Trials in Alzheimer’s Disease (CTAD) Meeting

November 18, 2013

TORONTO, Nov. 18, 2013 /PRNewswire/ – Transition Therapeutics Inc. (“Transition” or the “Company”) (NASDAQ: TTHI) (TSX: TTH) announced
ELND005 (scyllo-inositol) was featured in an oral and two poster
presentations at the recently completed 6th Annual Clinical Trials in
Alzheimer’s Disease meeting that occurred November 13-16 in San Diego,
CA. In addition, the conference included symposia that examined
“Agitation and Aggression in AD: a new target for drug development” and
“AD and Down Syndrome.”

The ELND005 presentations were entitled:

          "Effects of ELND005 (Scyllo-inositol) long term treatment on
          Amyloid related imaging abnormalities (ARIA) in Phase 2 AD

          "Dose selection for ELND005 (Scyllo-inositol) in neuropsychiatric
          clinical trials: Use of Modeling and simulations (M&S) of
          population pharmacokinetic model to estimate target drug

          "Effects of ELND005 (Scyllo-inositol) and Clozapine on social
          withdrawal behaviors: Differential Profiles in a PCP animal

About ELND005

ELND005 is an orally bioavailable small molecule that is being
investigated by Transition’s licensing partner, Elan, for multiple
neuropsychiatric indications on the basis of its proposed dual
mechanism of action, which includes b-amyloid anti-aggregation and
regulation of brain myo-inositol levels. An extensive clinical program
of Phase 1 and Phase 2 studies have been completed with ELND005 to
support clinical development, including the published Phase 2 study
ELND005-AD201 in AD. ELND005 is also being studied as a potential
treatment of agitation and aggression in Alzheimer’s disease (Study
ELND005-AG201), as a maintenance therapy of Bipolar Disorder Type I
(Study ELND005-BPD201) and as a therapy for those with Down syndrome
(Study ELND005-DS-201).

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. The Company’s lead CNS drug
candidate is ELND005 for the treatment of Alzheimer’s disease and
bipolar disorder. Transition’s lead metabolic drug candidate is TT-401
for the treatment of type 2 diabetes and accompanying obesity. The
Company’s shares are listed on the NASDAQ under the symbol “TTHI” and
the Toronto Stock Exchange under the symbol “TTH”. For additional
information about the Company, please visit www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be
superseded by more recent information we have disclosed in later press
releases, filings with the OSC, SEC or otherwise. Except for historical
information, this press release may contain forward-looking statements,
relating to expectations, plans or prospects for Transition, including
conducting clinical trials and potential efficacy of its products.
These statements are based upon the current expectations and beliefs of
Transition’s management and are subject to certain risks and
uncertainties that could cause actual results to differ materially from
those described in the forward-looking statements. These risks and
uncertainties include factors beyond Transition’s control and the risk
factors and other cautionary statements discussed in Transition’s
quarterly and annual filings with the Canadian commissions.

SOURCE Transition Therapeutics Inc.

Source: PR Newswire